NASDAQ:AUPH Stock Quote
Aurinia Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies to treat autoimmune and rare diseases
The company is dedicated to advancing its pipelines, particularly in developing treatments for conditions such as lupus nephritis, with a commitment to improving patient outcomes through scientifically driven solutions. Aurinia’s goal is to bring forward novel medications that address unmet medical needs and transform the standard of care in its therapeutic areas.
Frequently Asked Questions
Has Aurinia Pharmaceuticals received any awards or recognitions?
Aurinia Pharmaceuticals has received several accolades for its innovative approach and contribution to the pharmaceutical industry. The company has been recognized for its commitment to advancing treatment options for autoimmune diseases, reflecting its dedication to improving patient health outcomes.
How does Aurinia Pharmaceuticals contribute to the community?
Aurinia Pharmaceuticals is committed to corporate social responsibility and community engagement. The company supports various initiatives aimed at improving health literacy, providing patient support, and contributing to the advancement of medical research, reflecting its dedication to the welfare of the communities it serves.
How does Aurinia Pharmaceuticals engage with patients?
Aurinia Pharmaceuticals engages with patients through educational initiatives, support programs, and by fostering a patient-focused culture. The company seeks to understand the needs of patients with autoimmune diseases and provides resources that assist them in managing their conditions effectively.
How does Aurinia Pharmaceuticals ensure drug safety?
Aurinia Pharmaceuticals emphasizes drug safety through comprehensive clinical trials that assess the safety and efficacy of its products. The company adheres to strict regulatory guidelines established by the FDA and other health authorities, ensuring that its therapies are thoroughly evaluated before they are made available to patients.
How does Aurinia Pharmaceuticals protect its intellectual property?
Aurinia Pharmaceuticals actively protects its intellectual property through the filing of patents and trademarks related to its products and research innovations. This strategy is vital for maintaining a competitive edge in the biopharmaceutical industry and ensuring that the company can capitalize on its discoveries and advancements.
Is Aurinia Pharmaceuticals publicly traded?
Yes, Aurinia Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol AUPH. The company went public to raise capital for its research and development initiatives, allowing it to advance its portfolio of drugs aimed at treating autoimmune diseases.
What are the company's key products?
Aurinia Pharmaceuticals' key product is Lupkynis (voclosporin), which is used for the treatment of lupus nephritis. The company is also involved in developing additional therapeutics aimed at a variety of autoimmune disorders, reinforcing its commitment to improving patient care and treatment options.
What clinical trials has Aurinia Pharmaceuticals conducted?
Aurinia Pharmaceuticals has conducted numerous clinical trials, most notably the AURORA trial, which evaluated the safety and efficacy of Lupkynis in patients with lupus nephritis. These trials are critical for gathering data to support regulatory submissions and demonstrate the therapeutic benefits of its products.
What does Aurinia Pharmaceuticals Inc do?
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat autoimmune diseases. The company primarily targets diseases like lupus nephritis through its flagship product, Lupkynis (voclosporin), which received FDA approval as a treatment for this condition. Aurinia is committed to improving patient outcomes through scientific research and drug development.
What financial information is available for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals regularly releases financial reports detailing its revenues, expenses, and overall performance. Investors can access these financial statements and other relevant information on the company's investor relations website, allowing for informed decision-making regarding investment in AUPH shares.
What is Aurinia's research strategy?
Aurinia's research strategy focuses on leveraging its expertise in immunology and nephrology to develop targeted therapeutics for autoimmune diseases. The company is committed to advancing scientific knowledge in these fields and utilizing innovative approaches to tackle complex medical challenges.
What is Lupkynis?
Lupkynis, or voclosporin, is an oral immunosuppressant medication developed by Aurinia Pharmaceuticals. It is specifically indicated for the treatment of lupus nephritis, a serious kidney condition associated with systemic lupus erythematosus. By modulating the immune response, Lupkynis helps reduce inflammation and prevent further kidney damage in patients suffering from lupus nephritis.
What is the company's mission statement?
Aurinia Pharmaceuticals' mission is to improve the lives of patients with autoimmune diseases by developing innovative therapies that address their complex medical needs. The company is driven by science and is committed to translating research into effective treatments that enhance patient care.
What is the future outlook for Aurinia Pharmaceuticals?
The future outlook for Aurinia Pharmaceuticals appears promising, particularly with the continued growth and adoption of Lupkynis in the market. The company is focused on expanding its product pipeline and may pursue additional indications and collaborations to enhance its position as a leader in the autoimmune disease therapeutic landscape.
What is the primary focus of Aurinia Pharmaceuticals?
The primary focus of Aurinia Pharmaceuticals is the development of novel therapeutics for the treatment of autoimmune diseases, with a strong emphasis on kidney-related conditions such as lupus nephritis. The company aims to provide effective solutions that address unmet medical needs in these segments.
What is the significance of Lupkynis for lupus nephritis patients?
Lupkynis represents a significant advancement for lupus nephritis patients as it offers a new treatment option that has been shown to be effective in reducing disease activity and preserving kidney function. It fills a critical gap in therapy for a condition that can lead to severe health complications if left untreated.
What partnerships or collaborations does Aurinia have?
Aurinia Pharmaceuticals has engaged in various partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies. These relationships are essential for enhancing its research capabilities, accelerating drug development, and ultimately bringing innovative therapies to market more efficiently.
When was Aurinia Pharmaceuticals founded?
Aurinia Pharmaceuticals Inc was founded in 2010. The company was established with the aim of advancing innovative treatments for autoimmune and inflammatory diseases, leveraging its expertise in drug development to improve the quality of life for patients affected by these conditions.
Where is Aurinia Pharmaceuticals headquartered?
Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada. The location provides the company with access to a skilled workforce and proximity to research institutions, facilitating collaboration and innovation in drug development.
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 8.175
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 3:52 pm EDT on April 2nd, 2025
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 1.05B
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 128.40M shares outstanding.